Log in

West Pharmaceutical Services Stock Forecast, Price & News

+2.77 (+1.01 %)
(As of 09/18/2020 12:00 AM ET)
Today's Range
Now: $277.73
50-Day Range
MA: $272.55
52-Week Range
Now: $277.73
Volume1.61 million shs
Average Volume636,974 shs
Market Capitalization$20.51 billion
P/E Ratio73.28
Dividend Yield0.23%
West Pharmaceutical Services, Inc. manufactures and sells containment and delivery systems for injectable drugs and healthcare products in the United States, Germany, France, Other European countries, South Korea, and internationally. The company operates through two segments, Proprietary Products and Contract-Manufactured Products. The Proprietary Products segment offers stoppers and seals for injectable packaging systems; syringe and cartridge components, including custom solutions for the needs of injectable drug applications, as well as administration systems that enhance the safe delivery of drugs through advanced reconstitution, mixing, and transfer technologies; and films, coatings, and washing and sterilization processes and services to enhance the quality of packaging components. It also provides drug containment solutions, including CZ, a cyclic olefin polymer in the form of vials, syringes, and cartridges; and self-injection devices, as well as a range of integrated services, including analytical lab services, pre-approval primary packaging support and engineering development, regulatory expertise, and after-sales technical support. This segment serves biologic, generic, and pharmaceutical drug companies. The Contract-Manufactured Products segment is involved in the design, manufacture, and automated assembly of components and devices used in surgical, diagnostic, ophthalmic, injectable, and other drug delivery systems, as well as consumer products. This segment serves pharmaceutical, diagnostic, and medical device companies. The company distributes its products through its sales force and distribution network, as well as contract sales agents and regional distributors. The company was founded in 1923 and is headquartered in Exton, Pennsylvania.
Read More
West Pharmaceutical Services logo

Beat the Market (BTM) Rank

Analyst Opinion: 1.5Community Rank: 2.0Dividend Strength: 3.3Insider Behavior: 1.0Valuation: 0.6 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.69 out of 5 stars

Industry, Sector and Symbol

Industry Fabricated rubber products, not elsewhere classified
Sub-IndustryHealth Care Supplies



Sales & Book Value

Annual Sales$1.84 billion
Cash Flow$4.80 per share
Book Value$21.26 per share


Net Income$241.70 million


Market Cap$20.51 billion
Next Earnings Date10/22/2020 (Estimated)
+2.77 (+1.01 %)
(As of 09/18/2020 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive WST News and Ratings via Email

Sign-up to receive the latest news and ratings for WST and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles

West Pharmaceutical Services (NYSE:WST) Frequently Asked Questions

How has West Pharmaceutical Services' stock been impacted by COVID-19?

West Pharmaceutical Services' stock was trading at $147.83 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization. Since then, WST shares have increased by 87.9% and is now trading at $277.73.
View which stocks have been most impacted by COVID-19

Do Wall Street analysts recommend investors buy shares of West Pharmaceutical Services?

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for West Pharmaceutical Services in the last year. There are currently 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for West Pharmaceutical Services

When is West Pharmaceutical Services' next earnings date?

West Pharmaceutical Services is scheduled to release its next quarterly earnings announcement on Thursday, October 22nd 2020.
View our earnings forecast for West Pharmaceutical Services

How were West Pharmaceutical Services' earnings last quarter?

West Pharmaceutical Services Inc. (NYSE:WST) announced its earnings results on Thursday, July, 23rd. The medical instruments supplier reported $1.25 earnings per share for the quarter, beating the Thomson Reuters' consensus estimate of $0.91 by $0.34. The medical instruments supplier had revenue of $527.20 million for the quarter, compared to analyst estimates of $496.09 million. West Pharmaceutical Services had a net margin of 14.69% and a return on equity of 19.01%. The company's quarterly revenue was up 12.2% compared to the same quarter last year. During the same period last year, the firm posted $0.89 earnings per share.
View West Pharmaceutical Services' earnings history

How often does West Pharmaceutical Services pay dividends? What is the dividend yield for West Pharmaceutical Services?

West Pharmaceutical Services declared a quarterly dividend on Wednesday, July 15th. Shareholders of record on Wednesday, July 29th will be paid a dividend of $0.16 per share on Wednesday, August 5th. This represents a $0.64 dividend on an annualized basis and a yield of 0.23%. The ex-dividend date of this dividend is Tuesday, July 28th.
View West Pharmaceutical Services' dividend history

What guidance has West Pharmaceutical Services issued on next quarter's earnings?

West Pharmaceutical Services issued an update on its FY 2020 Pre-Market earnings guidance on Thursday, July, 23rd. The company provided EPS guidance of 4.15-4.25 for the period, compared to the Thomson Reuters consensus EPS estimate of $3.61. The company issued revenue guidance of $2.035-2.055 billion, compared to the consensus revenue estimate of $1.96 billion.

What price target have analysts set for WST?

2 brokerages have issued 12 month price targets for West Pharmaceutical Services' stock. Their forecasts range from $280.00 to $280.00. On average, they expect West Pharmaceutical Services' stock price to reach $280.00 in the next twelve months. This suggests a possible upside of 0.8% from the stock's current price.
View analysts' price targets for West Pharmaceutical Services

Who are some of West Pharmaceutical Services' key competitors?

What other stocks do shareholders of West Pharmaceutical Services own?

Based on aggregate information from My MarketBeat watchlists, some companies that other West Pharmaceutical Services investors own include NVIDIA (NVDA), AbbVie (ABBV), Johnson & Johnson (JNJ), Walt Disney (DIS), Visa (V), Mcdonald's (MCD), Alibaba Group (BABA), Home Depot (HD), Netflix (NFLX) and Walmart (WMT).

Who are West Pharmaceutical Services' key executives?

West Pharmaceutical Services' management team includes the following people:
  • Mr. Eric M. Green, CEO, Pres & Director (Age 49)
  • Mr. David A. Montecalvo, Sr. VP and Chief Operations & Supply Chain Officer (Age 54)
  • Mr. George Lloyd Miller, Sr. VP, Gen. Counsel & Corp. Sec. (Age 64)
  • Ms. Karen A. Flynn, Chief Commercial Officer & Sr. VP (Age 56)
  • Mr. William J. Federici, Advisor (Age 59)

What is West Pharmaceutical Services' stock symbol?

West Pharmaceutical Services trades on the New York Stock Exchange (NYSE) under the ticker symbol "WST."

Who are West Pharmaceutical Services' major shareholders?

West Pharmaceutical Services' stock is owned by a variety of institutional and retail investors. Top institutional shareholders include Vanguard Group Inc. (11.67%), Neuberger Berman Group LLC (2.64%), WCM Investment Management LLC (2.11%), Bamco Inc. NY (1.95%), Nuveen Asset Management LLC (1.02%) and Victory Capital Management Inc. (0.88%). Company insiders that own West Pharmaceutical Services stock include Annette F Favorite, Daniel Malone, David A Montecalvo, George Lloyd Miller and Silji Abraham.
View institutional ownership trends for West Pharmaceutical Services

Which major investors are selling West Pharmaceutical Services stock?

WST stock was sold by a variety of institutional investors in the last quarter, including AJO LP, Bank of New York Mellon Corp, Fisher Asset Management LLC, Neuberger Berman Group LLC, Federated Hermes Inc., AQR Capital Management LLC, American International Group Inc., and Principal Financial Group Inc.. Company insiders that have sold West Pharmaceutical Services company stock in the last year include Annette F Favorite, David A Montecalvo, George Lloyd Miller, and Silji Abraham.
View insider buying and selling activity for West Pharmaceutical Services

Which major investors are buying West Pharmaceutical Services stock?

WST stock was bought by a variety of institutional investors in the last quarter, including Vanguard Group Inc., FMR LLC, Charles Schwab Investment Management Inc., WCM Investment Management LLC, Skandinaviska Enskilda Banken AB publ, Prudential Financial Inc., Nuveen Asset Management LLC, and Victory Capital Management Inc..
View insider buying and selling activity for West Pharmaceutical Services

How do I buy shares of West Pharmaceutical Services?

Shares of WST can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is West Pharmaceutical Services' stock price today?

One share of WST stock can currently be purchased for approximately $277.73.

How big of a company is West Pharmaceutical Services?

West Pharmaceutical Services has a market capitalization of $20.51 billion and generates $1.84 billion in revenue each year. The medical instruments supplier earns $241.70 million in net income (profit) each year or $3.24 on an earnings per share basis. West Pharmaceutical Services employs 8,200 workers across the globe.

What is West Pharmaceutical Services' official website?

The official website for West Pharmaceutical Services is www.westpharma.com.

How can I contact West Pharmaceutical Services?

West Pharmaceutical Services' mailing address is 530 HERMAN O. WEST DRIVE, EXTON PA, 19341. The medical instruments supplier can be reached via phone at 610-594-2900 or via email at [email protected]

This page was last updated on 9/20/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.